Sofetabart mipitecan (Sofe-M), an investigational folate receptor α (FRα)–directed antibody-drug conjugate (ADC), yielded ...

Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal ...

Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable ...

Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in ...

Asked about the biggest misconception community providers hold about the referral process, Matthew J. Frigault, MD, clinical director of the Cellular Immunotherapy Program at Mass General Brigham ...

The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk ...

The acoustic coupling fluid is under substantive FDA review after a pivotal study of 44 patients reported improved ultrasound image quality during glioma surgery. In the phase 2 TRUCE-04 trial, ...

Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early ...

Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon). Patients with ...

With both CAR T-cell therapy and bispecific antibodies now available in early relapse, Adam D. Cohen, MD, director of Myeloma ...

In a phase 1 trial, CD19/CD20/CD22 CAR T cells produced complete responses in 83% of patients with relapsed/refractory B-cell ...